Project Grant R01CA311692
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $470K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $136,840 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2025 through May 11, 2028. This award funds research investigating replication gap suppression mechanisms in chemoresistant BRCA1 and BRCA2 (BRCA) mutant hereditary breast and ovarian cancers (HBOC). The project delivers fundamental cancer research aimed at...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $683,075 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective March 24, 2026, with a completion date of February 28, 2031. This research initiative investigates the mitotic functions of 53BP1 (tumor protein p53-binding protein 1) and its negative regulator TIRR (transient receptor potential channel-associated protein of iris),...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $524,110 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded June 1, 2026, with a completion date of May 31, 2031. This research initiative focuses on understanding and preventing genomic instability arising from one-ended DNA breaks in mammalian cells, with particular relevance to hereditary breast and ovarian cancer prevention. The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $211,112 to Harvard Medical School (President and Fellows of Harvard College) on August 14, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support investigator-initiated cancer research. The project, titled "Determining the Role of Replication Protein A in Polymerase Theta-Mediated End-Joining," will be conducted in Boston, Massachusetts, through March 31, 2029. The research addresses...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1.22M to the University of Massachusetts Boston under its Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2028. This project grant supports fundamental research to advance understanding of extracellular vesicles (EVs)—cell-derived, membrane-bound structures that carry biomolecules and serve as circulating biomarkers for disease diagnosis and therapeutic delivery. The research...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $707,798 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-refractory form shortly after...
- Federal Project Grant Award Summary Mayo Clinic has been awarded $741,738 by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) for a five-year project (June 1, 2026–May 31, 2031) investigating hypomorphic BRCA1 and BRCA2 variants and their role in cancer risk and treatment response. The research will establish the functional and clinical characteristics of reduced penetrance pathogenic variants (RPPVs)—a newly identified category of cancer risk...
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $167,500 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. This research grant funds the development and application of HARP-SEQ (a novel, highly sensitive methodology for mapping 3-methylcytidine [M3C] modifications in messenger RNA at single-nucleotide resolution). The project addresses...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning March 13, 2026, with completion targeted for February 28, 2029. This award supports the development and application of high-throughput tools designed to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events that drive oncogenic mechanisms...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $659,201 Project Grant effective June 1, 2026 through May 30, 2031 under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the integrated stress response (ISR) in glioblastoma (GBM) pathogenesis and therapeutic response. The project focuses on understanding how the interplay between phosphorylated eukaryotic translation initiation factor 2A...